Clinical Trials Browser

Phase 2 × Urinary Bladder Neoplasms × Gemcitabine × Clear all

NCT06770582 2026-04-15

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT04164082 2026-04-13

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT06388720 2026-04-13

IMGeS

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT02690558 2026-03-20

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Phase 2 Completed

39 enrolled 16 charts

Urinary Bladder Neoplasms

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT06488222 2026-03-11

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT05644041 2026-02-27

Intravesical Gem/Doce in Patients With NMIBC

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04630730 2026-01-21

Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT04553939 2026-01-02

Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05975307 2025-12-01

BCIRT-01

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT04386746 2025-11-17

GEMDOCE

Phase 2 Active not recruiting

27 enrolled 9 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06822010 2025-11-14

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT04216290 2025-11-12

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Phase 2 Active not recruiting

Urinary Bladder Neoplasms

NCT07189793 2025-09-24

OHAI-NMIBC-01

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07184021 2025-09-19

No Acronym

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT00082706 2025-09-09

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Phase 2 Active not recruiting

Urachal cancer, Urinary Bladder Neoplasms, Urethral Neoplasms

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06571708 2025-09-02

NeoSTOP-IT

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT05007106 2025-08-14

KEYVIBE-005

Phase 2 Completed

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05024734 2025-03-11

GAIN INST

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT00627432 2025-02-18

Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Phase 2 Completed

Urinary Bladder Neoplasms

NCT01697306 2025-01-30

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

Phase 2 Completed

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04871529 2024-12-30

Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)

Phase 2 Terminated

6 enrolled 12 charts

Urinary Bladder Neoplasms

NCT04861584 2024-12-04

Neoadjuvant Toripalimab in Combination with Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer Subjects

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT02177695 2024-09-19

COXEN

Phase 2 Completed

237 enrolled 20 charts

Urinary Bladder Neoplasms

NCT05531123 2024-07-12

Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT03558087 2024-06-27

Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing

Phase 2 Completed

76 enrolled 14 charts

Urinary Bladder Neoplasms

NCT04430036 2024-04-04

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Phase 2 Terminated

4 enrolled 9 charts

Urinary Bladder Neoplasms

NCT06227065 2024-01-26

POLO

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT02887248 2023-12-05

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

Phase 2 Terminated

3 enrolled 9 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04039867 2023-08-21

Evaluation of Oxaliplatin and Gemcitabine in Patients With Metastatic Bladder Cancer

Phase 2 Terminated

17 enrolled 9 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT00005644 2023-06-22

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00053209 2023-06-22

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00004223 2023-06-18

Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00777491 2022-06-15

Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer That Was Removed by Surgery

Phase 2 Completed

70 enrolled 18 charts

Urinary Bladder Neoplasms

NCT03294304 2021-12-16

BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy

Phase 2 Completed

43 enrolled 20 charts

Urinary Bladder Neoplasms

NCT03520231 2021-11-23

Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Kidney Neoplasms, Ureteral Neoplasms

NCT00478361 2020-10-09

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Phase 2 Completed

40 enrolled 7 charts

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT02665039 2019-10-08

VINGEM

Phase 2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT01589094 2019-10-02

Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

Phase 2 Completed

51 enrolled 11 charts

Urinary Bladder Neoplasms

NCT01611662 2019-07-29

Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer

Phase 2 Terminated

32 enrolled 6 charts

Urinary Bladder Neoplasms

NCT01191892 2019-05-16

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Phase 2 Completed

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT02560038 2018-11-28

Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer

Phase 2 Terminated

3 enrolled 9 charts

Urinary Bladder Neoplasms, Neoplasm Metastasis

NCT01089088 2018-10-26

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Phase 2 Completed

Urinary Bladder Neoplasms, Urethral Neoplasms

NCT00310011 2018-08-10

Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium

Phase 2 Completed

Urinary Bladder Neoplasms

NCT00089128 2018-07-12

Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Phase 2 Terminated

16 enrolled 4 charts

Urinary Bladder Neoplasms

NCT00268450 2018-07-12

Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery

Phase 2 Terminated

21 enrolled 4 charts

Urinary Bladder Neoplasms

NCT00055601 2018-06-15

Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer

Phase 2 Completed

97 enrolled 8 charts

Urinary Bladder Neoplasms

NCT00461851 2017-12-14

Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma

Phase 2 Completed

17 enrolled 10 charts

Urinary Bladder Neoplasms